318 related articles for article (PubMed ID: 36562884)
21. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
22. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology.
Shen LL; Li WW; Xu YL; Gao SH; Xu MY; Bu XL; Liu YH; Wang J; Zhu J; Zeng F; Yao XQ; Gao CY; Xu ZQ; Zhou XF; Wang YJ
Neurobiol Dis; 2019 Dec; 132():104567. PubMed ID: 31394202
[TBL] [Abstract][Full Text] [Related]
23. Tau, tau kinases, and tauopathies: An updated overview.
Montalto G; Ricciarelli R
Biofactors; 2023; 49(3):502-511. PubMed ID: 36688478
[TBL] [Abstract][Full Text] [Related]
24. Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A; Sigurdsson EM; Krishnamurthy PK
Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
[TBL] [Abstract][Full Text] [Related]
25. Targeting Tau Hyperphosphorylation
Turab Naqvi AA; Hasan GM; Hassan MI
Curr Top Med Chem; 2020; 20(12):1059-1073. PubMed ID: 31903881
[TBL] [Abstract][Full Text] [Related]
26. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
27. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
28. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
29. A mathematical model of multisite phosphorylation of tau protein.
Stepanov A; Karelina T; Markevich N; Demin O; Nicholas T
PLoS One; 2018; 13(2):e0192519. PubMed ID: 29408874
[TBL] [Abstract][Full Text] [Related]
30. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
Zhang X; Hernandez I; Rei D; Mair W; Laha JK; Cornwell ME; Cuny GD; Tsai LH; Steen JA; Kosik KS
J Biol Chem; 2013 Jul; 288(30):22042-56. PubMed ID: 23737518
[TBL] [Abstract][Full Text] [Related]
31. Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies.
Su J; Xiao Y; Wei L; Lei H; Sun F; Wang W; Yin J; Xiong R; Li S; Zhang P; Zhou Y; Wang X; Zheng J; Wang JZ
Sci Bull (Beijing); 2024 Apr; 69(8):1137-1152. PubMed ID: 38341350
[TBL] [Abstract][Full Text] [Related]
32. Tauopathy: A common mechanism for neurodegeneration and brain aging.
Saha P; Sen N
Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
34. Reinstated Activity of Human Tau-induced Enhanced Insulin Signaling Restricts Disease Pathogenesis by Regulating the Functioning of Kinases/Phosphatases and Tau Hyperphosphorylation in Drosophila.
Pragati ; Sarkar S
Mol Neurobiol; 2024 Feb; 61(2):982-1001. PubMed ID: 37674037
[TBL] [Abstract][Full Text] [Related]
35. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease.
Kumar P; Jha NK; Jha SK; Ramani K; Ambasta RK
J Alzheimers Dis; 2015; 43(2):341-61. PubMed ID: 25096626
[TBL] [Abstract][Full Text] [Related]
36. Hyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death.
Liu M; Sui D; Dexheimer T; Hovde S; Deng X; Wang KW; Lin HL; Chien HT; Kweon HK; Kuo NS; Ayoub CA; Jimenez-Harrison D; Andrews PC; Kwok R; Bochar DA; Kuret J; Fortin J; Tsay YG; Kuo MH
Mol Neurobiol; 2020 Nov; 57(11):4704-4719. PubMed ID: 32780352
[TBL] [Abstract][Full Text] [Related]
37. GSK3β-mediated tau hyperphosphorylation triggers diabetic retinal neurodegeneration by disrupting synaptic and mitochondrial functions.
Zhu H; Zhang W; Zhao Y; Shu X; Wang W; Wang D; Yang Y; He Z; Wang X; Ying Y
Mol Neurodegener; 2018 Nov; 13(1):62. PubMed ID: 30466464
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic strategies for tauopathies and drug repurposing as a potential approach.
Islam M; Shen F; Regmi D; Du D
Biochem Pharmacol; 2022 Apr; 198():114979. PubMed ID: 35219701
[TBL] [Abstract][Full Text] [Related]
39. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
Iqbal K; Grundke-Iqbal I
Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
